StockIQ.techEli Lilly and Company (LLY) Stock Analysis
Free AI-powered analysis and research for Eli Lilly and Company stock
Sector: Healthcare
LLY snapshot
Data as of 3 Nov 2026 close. Updated daily.
Eli Lilly and Company scores 96/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 95% of its 52-week range, up 58.6% over the past year. Latest reported figures show a profit margin of 31.9%, return on equity of 86.0% and revenue growth of +38.6%.
What is driving the score
- Strong Uptrend: +12
- MACD Bullish: +8
- High P/E (46.0): -10
- Strong Revenue Growth (38.6%): +8
- Excellent Profit Margin (31.9%): +10
- Weak Liquidity (1.39 Current Ratio): -5
- Excellent ROE (86.0%): +8
- High P/B (31.37): -5
- Strong Long-term Uptrend: +8
- Strong Rise (+58.6% over 1 year): +10
- Low Volume (0.4x): -3
- Near 52-Week High (95%): +5
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full LLY report
Eli Lilly and Company (LLY) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze LLY Now →📰 Latest Update
Eli Lilly Just Delivered Another Monster Quarter. But There’s More to This Story Than Weight-Loss Drugs
Tue, November 3, 2026 at 1:03 PM UTC 3 min read
Eli Lilly (NYSE: LLY) reported a strong third quarter, with revenue rising 38.6% to $24.40 billion, driven by a 53% increase in tirzepatide volume. CEO David Ricks emphasized the company's focus on diversifying its pipeline beyond weight-loss drugs, with three-fourths aimed at other diseases. Despite a year-to-date share increase of 30.44%, analysts project a 4.4% downside from the average target of $1,333.72, while Lilly's earnings estimates continue to rise, indicating potential for future growth.